University of New Mexico-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2021

  1. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients

    Breast Cancer Research and Treatment, Vol. 190, Núm. 3, pp. 477-489

2018

  1. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

    Breast Cancer Research and Treatment, Vol. 171, Núm. 2, pp. 273-282

2013

  1. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

    Oral Oncology, Vol. 49, Núm. 5, pp. 461-467

2012

  1. DR6 as a diagnostic and predictive biomarker in adult sarcoma

    PLoS ONE, Vol. 7, Núm. 5

2009

  1. GPR30 predicts poor survival for ovarian cancer

    Gynecologic Oncology, Vol. 114, Núm. 3, pp. 465-471

2007

  1. Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes

    Genes Chromosomes and Cancer, Vol. 46, Núm. 4, pp. 373-384

2006

  1. Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression

    Molecular Cancer, Vol. 5

2004

  1. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes incervical carcinoma

    BMC Cancer, Vol. 4

  2. Promoter Hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer

    Cancer Research, Vol. 64, Núm. 9, pp. 2994-2997

2003

  1. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome

    Molecular Cancer, Vol. 2